公开(公告)号：EP2908853A1

公开(公告)日：2015-08-26

申请号：EP13847469.7

申请日：2013-10-21

申请人： University of Rochester

发明人： PHIPPS, Richard, P. ,  WOELLER, Collynn, F. ,  FELDON, Steven, E.

IPC分类号： A61K39/00

CPC分类号： A61K38/177 ,  A61K9/0014 ,  A61K9/0048 ,  A61K38/1774 ,  C07K14/70503 ,  C12N15/1138 ,  C12N2310/113 ,  C12N2310/141

摘要： The present invention relates to methods of treating a condition involving excessive adipogenesis. This method relates to selecting a subject having a condition involving excessive adipogenesis and administering to the selected subject a composition comprising a Thy1 protein or polypeptide fragment thereof, or an agent that enhances Thy1 expression, under conditions effective to treat the condition. The present invention also relates to isolated nucleic acid molecules encoding a Thy1 protein or the fragment thereof and pharmaceutical formulations including such a protein or fragment thereof or an agent that enhances Thy1 expression and a pharmaceutically acceptable carrier. The present invention also relates to methods of inhibiting adipogenesis and/or decreasing adipocyte size, as well as methods of screening a candidate compound for its ability to influence adipogenesis.

摘要翻译： 本发明涉及治疗涉及过量脂肪生成的病症的方法。 该方法涉及选择具有过度脂肪形成的病症的受试者，并且在有效治疗病症的条件下，向所选受试者施用包含Thy1蛋白或其多肽片段或增强Thy1表达的药物。 本发明还涉及编码Thy1蛋白或其片段的分离的核酸分子和包含这种蛋白质或其片段的药物制剂或增强Thy1表达的药物和药学上可接受的载体。 本发明还涉及抑制脂肪形成和/或减少脂肪细胞大小的方法，以及筛选候选化合物以影响脂肪形成的能力的方法。

公开(公告)号：EP2908853B1

公开(公告)日：2018-12-05

申请号：EP13847469.7

申请日：2013-10-21

申请人： University of Rochester

发明人： PHIPPS, Richard, P. ,  WOELLER, Collynn, F. ,  FELDON, Steven, E.

IPC分类号： A61K38/17 ,  C07K14/705

CPC分类号： A61K38/177 ,  A61K9/0014 ,  A61K9/0048 ,  A61K38/1774 ,  C07K14/70503 ,  C12N15/1138 ,  C12N2310/113 ,  C12N2310/141

摘要： The present invention relates to methods of treating a condition involving excessive adipogenesis. This method relates to selecting a subject having a condition involving excessive adipogenesis and administering to the selected subject a composition comprising a Thy1 protein or polypeptide fragment thereof, or an agent that enhances Thy1 expression, under conditions effective to treat the condition. The present invention also relates to isolated nucleic acid molecules encoding a Thy1 protein or the fragment thereof and pharmaceutical formulations including such a protein or fragment thereof or an agent that enhances Thy1 expression and a pharmaceutically acceptable carrier. The present invention also relates to methods of inhibiting adipogenesis and/or decreasing adipocyte size, as well as methods of screening a candidate compound for its ability to influence adipogenesis.